Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Rugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Bardia, A., Hurvitz, S. A., O’Shaughnessy, J., Cortés, J., Diéras, V., Carey, L. A., Gianni, L., Piccart, M. J., Loibl, S., Goldenberg, D. M., Hong, Q., Olivo, M., Itri, L. M., & Kalinsky, K. (2022). Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. Npj Breast Cancer, 8(1). https://doi.org/10.1038/s41523-022-00467-1
Authors:
Hope S. Rugo
Sara M. Tolaney
Delphine Loirat
Kevin Punie
Aditya Bardia
Sara A. Hurvitz
Joyce O’Shaughnessy
Javier Cortés
Véronique Diéras
Lisa A. Carey
Luca Gianni
Martine J. Piccart
Sibylle Loibl
David M. Goldenberg
Quan Hong
Martin Olivo
Loretta M. Itri
Kevin Kalinsky
Affiliated Authors:
Kevin Kalinsky
Publication Type:
Article
Unique ID:
10.1038/s41523-022-00467-1
Publication Date:
Data Source:
Scopus

Record Created: